Arrowhead Pharmaceuticals Inc $ 41.02 -2.54 (-5.83%)
On watch
Volume:
1,290,373
Avg Vol (1m):
1,082,370
Market Cap $:
4.17 Bil
Enterprise Value $:
3.88 Bil
P/E (TTM):
455.75
P/B:
8.46
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 20.69 | ||
| Equity-to-Asset | 0.88 | ||
| Debt-to-Equity | 0.03 | ||
| Debt-to-EBITDA | 2.54 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 39.16 | ||
| Beneish M-Score | -2.13 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 0.82 | ||
| Net Margin % | 6.86 | ||
| ROE % | 2.86 | ||
| ROA % | 2.2 | ||
| ROC (Joel Greenblatt) % | 4.38 | ||
| 3-Year Revenue Growth Rate | 729.5 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 460.33 | ||
| PE Ratio without NRI | 460.33 | ||
| PB Ratio | 8.53 | ||
| PS Ratio | 29.7 | ||
| EV-to-EBIT | 3438.37 | ||
| EV-to-EBITDA | 669.82 | ||
| EV-to-Revenue | 28.24 | ||
| Current Ratio | 5.9 | ||
| Quick Ratio | 5.9 | ||
| Days Sales Outstanding | 3.33 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.81 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 23.54 | ||
| Price-to-Median-PS-Value | 0.24 | ||
| Price-to-Graham-Number | 13.45 | ||
| Earnings Yield (Greenblatt) % | 0.03 |